Media headlines about Fate Therapeutics (NASDAQ:FATE) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.5555324944828 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Wall Street Analysts Give Investors What They Want about: Fate Therapeutics, Inc. (FATE) (nasdaqplace.com)
- Lysosomal Storage Disorder Pipeline Analysis, Growth Drivers, Challenges, Competitive Landscape 2018 (medgadget.com)
- Should You Have this stock in Your Portfolio? Fate Therapeutics, Inc. (FATE) (nysestocks.review)
- Morning Buzz: MGM Resorts International (NYSE:MGM), Fate Therapeutics, Inc. (NASDAQ:FATE), Telaria, Inc. (NYSE … (journalfinance.net)
- Do Investors Feel Confident About Stock’s Future Direction? – Fate Therapeutics (NASDAQ:FATE) (nasdaqjournal.com)
Several analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $19.00 price objective on shares of Fate Therapeutics in a research note on Thursday, March 29th. ValuEngine upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. HC Wainwright cut shares of Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a research note on Tuesday, March 6th. UBS cut shares of Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 6th. Finally, Zacks Investment Research cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $15.00.
Fate Therapeutics opened at $10.44 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.20 and a current ratio of 7.20. Fate Therapeutics has a 12 month low of $9.53 and a 12 month high of $9.96. The stock has a market capitalization of $512.20 million, a price-to-earnings ratio of -10.24 and a beta of 1.74.
Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Fate Therapeutics had a negative net margin of 1,143.99% and a negative return on equity of 77.27%. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $1.82 million. Fate Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts forecast that Fate Therapeutics will post -1.03 earnings per share for the current fiscal year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.